Yükleniyor... / Loading...
This study investigates the feasibility and clinical value of liquid biopsy in patients with suspected metastatic lung cancer, using the InvisionFirst molecular panel. Patients over 18 with suspected stage IV lung cancer who have not previously had chemotherapy or a lung cancer biopsy may take part. It is a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥ 18 years; * Patients with clinico-radiological suspicious presentation of stage IV lung cancer; * No prior chemotherapy for locally advanced or metastatic NSCLC; * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 (Appendix 2); * Life expectancy \> 12 weeks; * No contraindication to systemic lung cancer treatment; * Covered by a medical insurance; * Signed informed consent prior to any study-specific procedure; * No prior biopsy or cytology for lung cancer diagnosis. Exclusion Criteria: * Pregnant or breastfeeding women; * Patient concurrently using other approved or investigational antineoplastic agents; * Major concurrent disease affecting cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures or results; * Prior history of malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the patient has been free of the disease for at least 3 years; * Patient requiring tutorship or curatorship.